Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Adalimumab

3

XVII.b Opportunistic pulmonary/systemic infections

2
Last update : 31/12/2013
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
TNF-alpha antagonists / inhibitors
5

Publications

Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease.
The Journal of pediatrics 2018 Oct;201;166-175.e3 2018 Oct
Miliary tuberculosis following negative latent tuberculosis infection screening prior to tumor necrosis factor-α antagonists: implications for management?
The Journal of rheumatology 2012 Jun;39;1297-8 2012 Jun
Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients.
Modern rheumatology 2012 Aug;22;498-508 2012 Aug
Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective.
Current rheumatology reviews 2011 Feb;7;77-87 2011 Feb

Powered by

  • ^
  • Contact
  • Cookies
  • About